UA79113C2 - Triazole derivatives as tachykinin receptor antagonists - Google Patents

Triazole derivatives as tachykinin receptor antagonists Download PDF

Info

Publication number
UA79113C2
UA79113C2 UA20041008646A UA20041008646A UA79113C2 UA 79113 C2 UA79113 C2 UA 79113C2 UA 20041008646 A UA20041008646 A UA 20041008646A UA 20041008646 A UA20041008646 A UA 20041008646A UA 79113 C2 UA79113 C2 UA 79113C2
Authority
UA
Ukraine
Prior art keywords
bis
group
chlorophenyl
alkyl
pyridin
Prior art date
Application number
UA20041008646A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of UA79113C2 publication Critical patent/UA79113C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
UA20041008646A 2002-04-26 2003-04-22 Triazole derivatives as tachykinin receptor antagonists UA79113C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37612102P 2002-04-26 2002-04-26
PCT/US2003/010681 WO2003091226A1 (fr) 2002-04-26 2003-04-22 Derives de triazole en tant qu'antagonistes des recepteurs de la tachykinine

Publications (1)

Publication Number Publication Date
UA79113C2 true UA79113C2 (en) 2007-05-25

Family

ID=29270766

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20041008646A UA79113C2 (en) 2002-04-26 2003-04-22 Triazole derivatives as tachykinin receptor antagonists

Country Status (31)

Country Link
US (1) US7320994B2 (fr)
EP (1) EP1501809B1 (fr)
JP (1) JP4559087B2 (fr)
KR (1) KR100755577B1 (fr)
CN (1) CN1312136C (fr)
AR (1) AR039329A1 (fr)
AT (1) ATE384053T1 (fr)
AU (1) AU2003230829B8 (fr)
BR (1) BRPI0309534B8 (fr)
CA (1) CA2483159C (fr)
CR (1) CR7548A (fr)
CY (1) CY1107221T1 (fr)
DE (1) DE60318697T2 (fr)
DK (1) DK1501809T3 (fr)
EA (1) EA007720B1 (fr)
EC (1) ECSP045391A (fr)
ES (1) ES2298513T3 (fr)
HK (1) HK1073304A1 (fr)
HR (1) HRP20041008B1 (fr)
IL (2) IL164675A0 (fr)
MX (1) MXPA04010622A (fr)
MY (1) MY141559A (fr)
NO (1) NO333647B1 (fr)
NZ (1) NZ535886A (fr)
PE (1) PE20040600A1 (fr)
PL (1) PL212090B1 (fr)
PT (1) PT1501809E (fr)
TW (1) TWI265807B (fr)
UA (1) UA79113C2 (fr)
WO (1) WO2003091226A1 (fr)
ZA (1) ZA200408670B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000821A1 (fr) * 2003-06-12 2005-01-06 Eli Lilly And Company Antagonistes du recepteur tachykinine
JP4959336B2 (ja) * 2003-10-24 2012-06-20 イーライ リリー アンド カンパニー ｛２−［１−（３，５−ビストリフルオロメチルベンジル）−５−ピリジン−４−イル−１ｈ−［１，２，３］トリアゾル−４−イル］−ピリジン−３−イル｝−（２−クロロフェニル）−メタノンの新規の結晶形態
WO2006083711A1 (fr) * 2005-02-01 2006-08-10 Eli Lilly And Company Antagonistes du recepteur de la tachykinine
JP4874958B2 (ja) 2005-03-30 2012-02-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピリジン誘導体を含有する抗真菌剤
US8952176B2 (en) * 2005-06-07 2015-02-10 Shionogi & Co., Ltd. Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity
ES2353724T3 (es) * 2005-07-25 2011-03-04 F. Hoffmann-La Roche Ag Derivados de triazol substitutidos y su uso como antagonistas del receptor neuroquinina 3.
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
NZ574153A (en) * 2006-08-18 2011-12-22 Syngenta Ltd Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs
US8183264B2 (en) 2006-09-21 2012-05-22 Eisai R&D Managment Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
JP5443168B2 (ja) 2006-12-20 2014-03-19 イーライ リリー アンド カンパニー ｛２−［１−（３，５−ビス−トリフルオロメチル−ベンジル）−５−ピリジン−４−イル−１ｈ−［１，２，３］トリアゾール−４−イル］−ピリジン−３−イル｝−（２−クロロフェニル）−メタノンの調製において有用な新規の中間体及び方法
RU2010102994A (ru) * 2007-08-08 2011-09-20 Ньюросерч А/С (DK) Новые производные 1,2,3-триазола, полезные в качестве модуляторов никотиновых ацетилхолиновых рецепторов
GB0722077D0 (en) 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
AU2009263037B2 (en) * 2008-06-26 2011-10-06 Amgen Inc. Alkynyl alcohols as kinase inhibitors
GB0823002D0 (en) * 2008-12-17 2009-01-28 Syngenta Participations Ag Isoxazoles derivatives with plant growth regulating properties
WO2013004766A1 (fr) 2011-07-04 2013-01-10 Ferrari Giulio Antagonistes des récepteurs nk-1 pour traiter une néovascularisation cornéenne
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
CA3213864A1 (fr) * 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Regime posologique de tradipitant
US10287287B2 (en) 2015-08-17 2019-05-14 Eli Lilly And Company Process development of a pyridine-containing NK-1 receptor antagonist
LT3464271T (lt) 2016-05-31 2020-09-10 Kalvista Pharmaceuticals Limited Pirazolo dariniai kaip plazmos kalikreino inhibitoriai
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
CN111093671A (zh) 2017-09-13 2020-05-01 万达制药公司 以托吡坦对特应性皮炎的改进治疗
AU2018367623B2 (en) * 2017-11-17 2024-03-28 Vanda Pharmaceuticals Inc. Method of treatment of gastrointestinal diseases with tradipitant
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
IL274557B2 (en) 2017-11-29 2024-09-01 Kalvista Pharmaceuticals Ltd Dosage forms containing a plasma kallikrein inhibitor
EP4371613A3 (fr) 2018-02-26 2024-07-24 Ospedale San Raffaele S.r.l. Composés destinés à être utilisés dans le traitement de la douleur oculaire
US20210228555A1 (en) * 2018-06-08 2021-07-29 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
BR112020015484A2 (pt) * 2018-09-28 2021-04-27 Vanda Pharmaceuticals Inc. métodos para tratamento de um sujeito prestes a se envolver em uma atividade que implica em movimento indutor de enjoo e de um sujeito com enjoo de movimento ou pelo menos um sintoma de enjoo de movimento, composto, e, composição farmacêutica
EP3890735A1 (fr) 2018-12-03 2021-10-13 Vanda Pharmaceuticals Inc. Méthode de traitement avec le tradipitant
WO2020132513A1 (fr) 2018-12-21 2020-06-25 Vanda Pharmaceuticals Inc. Traitement amélioré de dermatite atopique au moyen de tradipitant
EP4010333A1 (fr) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Inhibiteurs de la kallicréine plasmatique
WO2021173641A1 (fr) 2020-02-25 2021-09-02 Vanda Pharmaceuticals Inc. Traitement amélioré de dermatite atopique au moyen de tradipitant
WO2021180885A1 (fr) 2020-03-11 2021-09-16 Ospedale San Raffaele S.R.L. Traitement d'une déficience en cellules souches
JP2023520369A (ja) 2020-03-26 2023-05-17 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる下気道感染症の治療
CA3173697A1 (fr) 2020-04-03 2021-10-07 Mike TROWER Antagoniste du recepteur de nk-1 pour le traitement d'une maladie choisie parmi une septicemie, un choc septique, un syndrome de detresse respiratoire aigue (ards) ou un syndrome de dysfonctionnement des organes multiples (mods
CN113563306B (zh) * 2020-04-28 2022-07-01 新发药业有限公司 一种2-(4-苯氧基苯基)-6-(哌啶-4-)基烟酰胺的制备方法
BR112022024208A2 (pt) 2020-06-02 2022-12-20 Nerre Therapeutics Ltd Antagonistas do receptor de neurocinina (nk)-1 para uso no tratamento de condições de fibrose pulmonar promovidas por lesão mecânica aos pulmões
CN111662235B (zh) * 2020-06-23 2023-12-22 黄淮学院 一种苯甲酰基哒嗪衍生物及其制备方法
WO2023019084A1 (fr) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Traitement de l'accommodation gastrique avec du tradipitant
WO2023034718A1 (fr) 2021-08-31 2023-03-09 Vanda Pharmaceuticals Inc. Traitement d'une infection des voies respiratoires inférieures avec du tradipitant
WO2024138040A1 (fr) 2022-12-21 2024-06-27 Vanda Pharmaceuticals Inc. Méthodes de traitement par tradipitant

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL50699A0 (en) 1975-10-28 1976-12-31 Ici America Inc Triazole derivatives
AU7947594A (en) * 1993-10-27 1995-05-22 Merck Sharp & Dohme Limited Substituted amides as tachykinin antagonists
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
US5998444A (en) 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
AU2633897A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Solid phase and combinatorial synthesis of substituted 1,2,3-triazoles and of arrays of substituted 1,2,3-triazoles
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
DK0915880T3 (da) 1996-07-24 2008-02-11 Bristol Myers Squibb Pharma Co Azolotriaziner og pyrimidiner
BR9811821A (pt) 1997-08-06 2000-08-15 Lilly Co Eli 2-acilaminopropanaminas como antagonistas de receptores de taquicinina
WO2001044200A2 (fr) * 1999-12-17 2001-06-21 Schering Corporation Antagonistes selectifs de la neurokine
TWI287003B (en) 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
DE10036818A1 (de) * 2000-07-28 2002-02-07 Solvay Pharm Gmbh Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten
JP2002123925A (ja) 2000-10-13 2002-04-26 Fuji Photo Film Co Ltd 磁気記録媒体
PT1501808E (pt) * 2002-04-26 2008-09-26 Lilly Co Eli Antagonistas de receptores taquiquininas

Also Published As

Publication number Publication date
MXPA04010622A (es) 2005-01-25
BRPI0309534B1 (pt) 2017-11-07
AU2003230829A1 (en) 2003-11-10
CN1312136C (zh) 2007-04-25
PL373504A1 (en) 2005-09-05
EP1501809A1 (fr) 2005-02-02
AU2003230829B8 (en) 2008-12-11
DE60318697D1 (de) 2008-03-06
US20050239786A1 (en) 2005-10-27
PL212090B1 (pl) 2012-08-31
DE60318697T2 (de) 2009-01-08
US7320994B2 (en) 2008-01-22
CA2483159C (fr) 2010-08-10
TWI265807B (en) 2006-11-11
ES2298513T3 (es) 2008-05-16
HK1073304A1 (en) 2005-09-30
WO2003091226A1 (fr) 2003-11-06
HRP20041008B1 (hr) 2012-10-31
EA200401431A1 (ru) 2005-06-30
EA007720B1 (ru) 2006-12-29
DK1501809T3 (da) 2008-05-13
PE20040600A1 (es) 2004-09-15
CN1646502A (zh) 2005-07-27
NO333647B1 (no) 2013-07-29
CY1107221T1 (el) 2012-11-21
EP1501809B1 (fr) 2008-01-16
CR7548A (es) 2006-12-01
PT1501809E (pt) 2008-03-18
CA2483159A1 (fr) 2003-11-06
AU2003230829B2 (en) 2008-12-04
TW200306824A (en) 2003-12-01
HRP20041008A2 (en) 2004-12-31
NO20045120L (no) 2004-12-07
JP4559087B2 (ja) 2010-10-06
JP2005536458A (ja) 2005-12-02
KR20040104634A (ko) 2004-12-10
MY141559A (en) 2010-05-14
KR100755577B1 (ko) 2007-09-12
ECSP045391A (es) 2005-01-03
AR039329A1 (es) 2005-02-16
IL198122A0 (en) 2009-12-24
ATE384053T1 (de) 2008-02-15
IL164675A0 (en) 2005-12-18
BRPI0309534B8 (pt) 2021-05-25
ZA200408670B (en) 2005-10-26
BR0309534A (pt) 2005-02-01
NZ535886A (en) 2007-07-27

Similar Documents

Publication Publication Date Title
UA79113C2 (en) Triazole derivatives as tachykinin receptor antagonists
US7262212B2 (en) 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles
TW467899B (en) Benzoheterocyclic derivatives
CA2896875C (fr) Composes de thiadiazole, analogues de ceux-ci et methodes destinees a traiter les affections liees a un deficit en smn
RU2259360C2 (ru) Производные бензодиазепина и лекарственное средство, их содержащее
TW591022B (en) Tetrahydropyridino or piperidino heterocyclic derivatives
JP4895476B2 (ja) タキキニン受容体アンタゴニスト
CA2880273A1 (fr) Analogues de pyridazine 1,4-disubstituee et procedes de traitement de troubles lies a une deficience en smn
EP3704107B1 (fr) Composés multicycliques en tant que modulateurs du récepteur de farnésoïde x
CA2991572A1 (fr) 6-amino-quinoline-3-carbonitriles utilises comme modulateurs de la kinase cot
US6015825A (en) Triazole antifungal agents
JP4401384B2 (ja) グルタミン酸受容体アンタゴニストであるイミダゾール誘導体
CN1875016B (zh) 咪唑衍生物
JP4571631B2 (ja) イミダゾール誘導体ｉｉｉ
JPH08301868A (ja) 置換ヘテロ環
JP3752130B2 (ja) 掻痒治療用新規４−アリールピペリジン誘導体
JP2004509870A (ja) ヒスタミンｈ１およびヒスタミンｈ３双方のアゴニストまたはアンタゴニストとしての置換イミダゾール